Related Experiment Videos
TPA: is it worth the price?
1Coronary Care Unit, Jewish Hospital at Washington University, St. Louis, MO 63110.
American Heart Journal
|November 1, 1987
Summary
Tissue plasminogen activator (TPA) shows higher reperfusion rates but streptokinase has a proven track record and lower cost. Further research is needed to establish TPA
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy is crucial for treating myocardial infarction.
- Tissue plasminogen activator (TPA) and streptokinase are key thrombolytic agents.
- Comparing the efficacy and safety of TPA versus streptokinase is essential.
Purpose of the Study:
- To evaluate the relative merits of TPA and streptokinase in thrombolytic therapy.
- To analyze existing evidence on reperfusion rates, myocardial salvage, and clinical outcomes.
- To inform clinical decision-making regarding the choice of thrombolytic agent.
Main Methods:
- Review and synthesis of existing clinical evidence and expert consensus.
- Comparative analysis of reported efficacy, safety profiles, and cost-effectiveness.
- Assessment of treatment protocols and potential for future refinements.
Main Results:
- TPA demonstrates higher reperfusion rates, especially after 4 hours, but with potentially limited myocardial salvage.
- Streptokinase offers a proven survival benefit and a low complication rate.
- TPA has theoretical advantages (less systemic activation, shorter half-life) but unproven clinical relevance.
Conclusions:
- Streptokinase remains a cost-effective choice due to its established track record and lower price.
- Additional evidence is required to confirm TPA's safety and efficacy.
- Future developments may enhance TPA's performance and reduce its cost, influencing future treatment choices.